Odiparcil QT Definitive Study

GlaxoSmithKline (GSK)

Status and phase: Terminated; Phase 1

Conditions: Atrial Fibrillation; Fibrillation, Atrial

Treatments: Drug: Odiparcil

Study type: Interventional

Funder types: Industry

Identifiers

NCT00437242

ITI103221

Details and patient eligibility

About

This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Healthy volunteers

Exclusion:

• Cardiac abnormalities
• Hepatic or renal insufficiency
• Anti-coagulant medications
• Bleeding history

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind